T1087

Valacyclovir hydrochloride (Valaciclovir hydrochloride) is an acyclovir prodrug that, upon metabolism, inhibits viral DNA replication.

CP-547632 hydrochloride is a well-tolerated and orally-bioavailable inhibitor of the VEGFR-2 and basic FGF kinases (IC50s: 11 nM and 9 nM) with antitumor efficacy.

CP-547632 is an orally available and potent, ATP-competitive dual inhibitor of VEGFR-2 and FGF kinase F with IC50s of 11 nM and 9 nM, respectively. CP-547632 is selective, with higher selectivity for VEGFR2 and bFGF than for EGFR, PDGFRβ and related tyrosine kinases (TKs). PDGFRβ and related tyrosine kinases (TKs) CP-547632 has antitumour activity.

CP-96021 hydrochloride is a potent and orally active antagonist of leukotriene D4 (LTD4)/platelet activating factor receptor (Kis: 34 nM and 37 nM).

CP-96486 is a potent and orally active antagonist of leukotriene D4 (LTD4) and platelet activating factor (PAF) receptors, with inhibitory constants (Kis) of 20 and 24 nM, respectively.

CP-060 is a potent Ca2+ antagonist and inhibits Ca2+ overload with antioxidant and cardioprotective activities.

CPA inhibitor (Carboxypeptidase inhibitor) is a potent carboxypeptidase A (CPA) inhibitor with a Ki of 0.32 μM.

CP-809101 hydrochloride is a potent and selective 5-HT2C receptor agonist with pEC50 values of 9.96 for human 5-HT2C, 7.19 for 5-HT2B, and 6.81 for 5-HT2A receptors.

CPDA is a new potent inhibitor of SH2 domain-containing inositol phosphatase 2 (SHIP2).

CP5V is a rationally designed PROTAC molecule composed of ligands for von Hippel–Lindau and cyclin-dependent kinase, which selectively induces degradation of Cdc20 by tethering it to the VHL/VBC E3 ligase complex, leading to ubiquitination and proteasomal degradation, mitotic arrest, and suppression of cancer cell proliferation, thereby serving as a mechanistic tool for cell cycle and oncology research.

CPFX2090, a cephalosporin antibacterial compound.

Valacyclovir (Valaciclovir) is an orally active antiviral drug for herpes simplex, herpes zoster, and herpes B, inhibiting HSV-1 W with an IC50 of 2.9 μg/ml. Valacyclovir is a prodrug of Aciclovir [1] [2] [3] [4] [5].